BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 8598456)

  • 1. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
    Williams NS; Engelhard VH
    J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
    Williams NS; Engelhard VH
    J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
    Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
    J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K; Bonardelle D; Bobé P; Kiger N
    Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
    Lewinsohn DM; Bement TT; Xu J; Lynch DH; Grabstein KH; Reed SG; Alderson MR
    J Immunol; 1998 Mar; 160(5):2374-9. PubMed ID: 9498779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
    J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis.
    Spielman J; Lee RK; Podack ER
    J Immunol; 1998 Dec; 161(12):7063-70. PubMed ID: 9862744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
    Li Q; Nakadai A; Takeda K; Kawada T
    Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms.
    Smith DJ; McGuire MJ; Tocci MJ; Thiele DL
    J Immunol; 1997 Jan; 158(1):163-70. PubMed ID: 8977187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte function-associated antigen-1-dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL.
    Kojima H; Eshima K; Takayama H; Sitkovsky MV
    J Immunol; 1997 Sep; 159(6):2728-34. PubMed ID: 9300693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
    Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
    J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells.
    Yasukawa M; Ohminami H; Yakushijin Y; Arai J; Hasegawa A; Ishida Y; Fujita S
    J Immunol; 1999 May; 162(10):6100-6. PubMed ID: 10229852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection.
    Zelinskyy G; Balkow S; Schimmer S; Schepers K; Simon MM; Dittmer U
    Virology; 2004 Dec; 330(2):365-74. PubMed ID: 15567431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis.
    Vergelli M; Hemmer B; Muraro PA; Tranquill L; Biddison WE; Sarin A; McFarland HF; Martin R
    J Immunol; 1997 Mar; 158(6):2756-61. PubMed ID: 9058810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theiler's virus infection of genetically susceptible mice induces central nervous system-infiltrating CTLs with no apparent viral or major myelin antigenic specificity.
    Lin X; Pease LR; Murray PD; Rodriguez M
    J Immunol; 1998 Jun; 160(11):5661-8. PubMed ID: 9605173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells.
    Lee RK; Spielman J; Zhao DY; Olsen KJ; Podack ER
    J Immunol; 1996 Sep; 157(5):1919-25. PubMed ID: 8757310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated alpha beta-CD8+, but not alpha alpha-CD8+, TCR-alpha beta+ murine intestinal intraepithelial lymphocytes can mediate perforin-based cytotoxicity, whereas both subsets are active in Fas-based cytotoxicity.
    Gelfanov V; Gelfanova V; Lai YG; Liao NS
    J Immunol; 1996 Jan; 156(1):35-41. PubMed ID: 8598484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H; Schmitt-Verhulst AM; Guimezanes A
    J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.